Liver cirrhosis is a condition in which liver deteriorates and gradually ceases the liver function. The healthy tissues of the liver are replaced by the scar tissues that block the blood flow in the liver. The main functions of the liver include removal of waste products, making new proteins, producing bile, and processing of the nutrients. The building up of scar tissue gets worse throughout the period and causes chronic liver failure which is also known as end stage liver disease. Chronic hepatitis C, alcoholism, non-alcoholic fatty liver disease, chronic hepatitis B and autoimmune liver disease are observed as the major causes of liver cirrhosis. Liver cirrhosis can be symptomatized by weakness, fatigue, weight loss, bloating of the abdomen, jaundice, itching, and nausea. Rohto Pharmaceutical Co., Ltd. is in the process of developing mesenchymal stem cell as a cell therapy for the treatment of liver cirrhosis. Pfizer, Inc. is in the process of developing pregabalin as a CACNA2D1 protein modulators for the treatment of liver cirrhosis. Some of the companies having the pipeline of liver cirrhosis include Conatus Pharmaceuticals, Inc., Pfizer, Inc., Prism Pharma Co., Ltd., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.